Spironolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The IMPRESS‐AF Trial

BACKGROUND: Patients with permanent atrial fibrillation have poor outcomes, exercise capacity, and quality of life even on optimal anticoagulation. Based on mechanistic and observational data, we tested whether the mineralocorticoid receptor antagonist spironolactone can improve exercise capacity, E...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Am Heart Assoc
Huvudupphovsmän: Shantsila, Eduard, Shahid, Farhan, Sun, Yongzhong, Deeks, Jonathan, Calvert, Melanie, Fisher, James P., Kirchhof, Paulus, Gill, Paramjit S., Lip, Gregory Y. H.
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley and Sons Inc. 2020
Ämnen:
Original Research
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7726985/
https://ncbi.nlm.nih.gov/pubmed/32909497
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.119.016239
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk